|
Cost-effectiveness of the LABA/LAMA dual bronchodilator indacaterol/glycopyrronium in a Swedish healthcare setting |
Price D, Keininger D, Costa-Scharplatz M, Mezzi K, Dimova M, Asukai Y, Stallberg B |
|
|
Record Status This is an economic evaluation that meets the criteria for inclusion on NHS EED. Bibliographic details Price D, Keininger D, Costa-Scharplatz M, Mezzi K, Dimova M, Asukai Y, Stallberg B. Cost-effectiveness of the LABA/LAMA dual bronchodilator indacaterol/glycopyrronium in a Swedish healthcare setting. Respiratory Medicine 2014; 108(12): 1786-1793 Indexing Status Subject indexing assigned by NLM MeSH Aged; Albuterol /analogs & Androstadienes /economics /therapeutic use; Bronchodilator Agents /administration & Cost-Benefit Analysis; Double-Blind Method; Drug Combinations; Drug Costs /statistics & Drug Therapy, Combination; Female; Fluticasone; Forced Expiratory Volume /drug effects; Glycopyrrolate /administration & Humans; Indans /administration & Male; Middle Aged; Monte Carlo Method; Pulmonary Disease, Chronic Obstructive /drug therapy /economics /physiopathology; Quinolones /administration & Salmeterol Xinafoate; Sweden; derivatives /economics /therapeutic use; dosage /economics /therapeutic use; dosage /economics /therapeutic use; dosage /economics /therapeutic use; dosage /economics /therapeutic use; numerical data AccessionNumber 22014039248 Date bibliographic record published 11/12/2014 |
|
|
|